GSK3858279 in Healthy Volunteers and Knee Osteoarthritis

Phase 1, randomised, double-blind trial of GSK3858279 in knee osteoarthritis (OA) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events up to 141 days, Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis up to 141 days and 4 more. Started May 2018; status: completed.